Pediapharm Announces Global Exclusive Licensing Agreement for Relaxa(R), an Established Canadian Product With Existing Revenues - Seite 3

The forward-looking statements contained in this news release are made as of the date of this release. Except as required by applicable law, the Corporation disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking information reflects the current expectations or belief of the Corporation based on information currently available and such information is subject to a number of assumptions, risks and uncertainties described in details at pp. 35 to 41 of the Management Information Circular of Chelsea Acquisition Corporation dated November 12, 2013 available on SEDAR at www.sedar.com and other risks associated with being a specialty pharmaceutical company.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

(1)	Understanding the Prevalence and Impact of Constipation in Canada. A Special Report from the Canadian Digestive Health Foundation. Feb 2014
(2)	van den Berg MM, Benninga MA, Di Lorenzo C. Epidemiology of childhood constipation: A systematic review. Am J Gastroenterol 2006;101:2401-9
(3)	Paediatr Child Health 2011;16(10):661-5 Managing functional constipation in children

Sylvain Chretien, President and Chief Executive Officer
Pediapharm Inc.
514-762-2626 ext. 201
[e-mail]

Roland Boivin, Chief Financial Officer
Pediapharm Inc.
514-762-2626 ext. 202
[e-mail]

Frank Candido
Direct Financial Strategies and Communication Inc.
514-969-5530
[e-mail]